Replies to post #238460 on Amarin Corp Plc (AMRN)

[venus537]

From a layman's perspective this just SUCKS as the generics have no intention of selling Vascepa strictly using the MARINE label.

Since there is no way to enforce doctors to follow the MARINE label the judge is basically allowing an argument for generics to circumvent the Reduce-it label.

[Restingzebra]

I agree. I too am confused as to why Reduce-it is important to this case. It was an outcome study. And as Elf pointed out so was Jellis. For that matter the Anchor CRL was issued because of doubt about lowering CVD risk not lipid altering. And CVD risk is not appropriate to this case. So what does Reduce-it bring to the table?
And maybe AMRN feels the same and has made the strategic decision that it is not worth releasing these docs to get it entered. Would greatly appreciate any explanation regarding why Reduce-it is so important. Thanks to all for the "robust" discussion. Sorry I couldn't resist.